Karyopharm Therapeutics Inc (NASDAQ:KPTI) rose 5.5% on Friday . The stock traded as high as $8.07 and last traded at $8.03, approximately 2,589,127 shares were traded during trading. An increase of 41% from the average daily volume of 1,841,581 shares. The stock had previously closed at $7.61.
KPTI has been the subject of several recent analyst reports. ValuEngine upgraded Zillow Group from a “hold” rating to a “buy” rating in a research note on Thursday. Wedbush set a $11.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Monday, July 8th. Robert W. Baird reiterated an “outperform” rating and set a $25.00 price target (up from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. BidaskClub upgraded shares of Zumiez from a “sell” rating to a “hold” rating in a report on Saturday, June 22nd. Finally, Zacks Investment Research upgraded shares of Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Saturday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $17.41.
The firm has a fifty day simple moving average of $6.37. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.25). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.75 million. Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. On average, equities research analysts expect that Karyopharm Therapeutics Inc will post -3.79 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ridgeback Capital Investments L.P. acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at $36,967,000. FMR LLC increased its holdings in Karyopharm Therapeutics by 51.5% in the fourth quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after purchasing an additional 637,357 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in Karyopharm Therapeutics by 4.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 1,866,778 shares of the company’s stock valued at $10,902,000 after purchasing an additional 74,234 shares during the period. Emerald Advisers LLC increased its holdings in Karyopharm Therapeutics by 3.5% in the first quarter. Emerald Advisers LLC now owns 1,508,094 shares of the company’s stock valued at $8,807,000 after purchasing an additional 51,621 shares during the period. Finally, Frontier Capital Management Co. LLC increased its holdings in Karyopharm Therapeutics by 311.9% in the first quarter. Frontier Capital Management Co. LLC now owns 683,363 shares of the company’s stock valued at $3,991,000 after purchasing an additional 517,464 shares during the period. Institutional investors and hedge funds own 84.20% of the company’s stock.
About Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Recommended Story: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.